tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

CorMedix sees FY25 pro forma revenue $325M-$350M

Sees Pro forma 2025 Synergized Adjusted EBITDA: $165M – $185M; DefenCath 2025 Revenue: $200M – $215M.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1